Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers

CINCINNATI–(BUSINESS WIRE)–Kurome Therapeutics, a preclinical stage company focused on developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease-modifying genes, today announced the conclusion of a Series A funding of $15 million. The round was co-led by Medicxi and Affinity Asset Advisors with the participation of founding investor CincyTech and other existing seed investors.

“We are delighted to have the support of exceptional investors. This funding allows us to expand our R&D program to substantially reduce compound selection as we identify our first development candidate prior to submitting the IND application,” said Kurome Chief Executive Officer and Chief Scientific Officer Jan Rosenbaum, PhD .

The funding will support the preclinical progress of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of both targeted therapy and chemotherapy drugs through adaptive resistance mechanisms, with co-opted IRAK1/4-mediated immune signaling pathways for survival. The biology currently under investigation was discovered by Daniel Starczynowski, PhD, who is principal investigator and co-leader of the hematologic malignancies program at the Cincinnati Children’s Cancer and Blood Diseases Institute, and a leading expert in IRAK 1/4 signaling pathways in cancer. These treatments are initially aimed at improving outcomes in patients with acute myeloid leukemia (AML) with a poor prognosis, but will seek to expand the focus to a range of hematopoietic cancers, including pre-leukemic conditions such as myelodysplastic syndromes ( MDS), as well as certain solid tumors in which dysregulated IRAK1/4 signaling and inflammation may play a pathogenic role in tumorigenesis.

“We are delighted to align with the leading experts in the IRAK1/4 signaling path and are impressed with the level of development and data Kurome has generated to date,” said Daniel Heller, General Partner and Chief Investment Officer at Affinity Asset Advisors.

Launched in 2020, Kurome received its first seed funding led by CincyTech based on research at the Cincinnati Children’s Hospital Medical Center in partnership with the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (NCATS).

“In multifactorial hematologic malignancies such as AML, we are excited about the early clinical data of combined IRAK4 and FLT3 inhibition in patients. The Kurome team has generated compelling preclinical data suggesting a differentiated approach with potential advantages over others in this emerging field. space,” said Aaron Kantoff, Venture Partner at Medicxi.

Aaron Kantoff, Venture Partner at Medicxi, and Daniel Heller, General Partner and Chief Investment Officer at Affinity Asset Advisors, will join Kurome Therapeutics’ board of directors.

About Kurome Therapeutics

Kurome® Therapeutics is a preclinical company developing novel therapies that undermine cancer’s ability to escape treatment. Founded on research at the Cincinnati Children’s Hospital Medical Center in collaboration with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), Kurome is developing a series of combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that have IRAK1 co-opted /4-mediated immune signaling pathways for survival.

Comments are closed.